RecruitingInterventional

An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors

NCT ID: NCT05080166Sponsor: Dana-Farber Cancer InstituteLast updated: 2026-02-24

Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Detailed description

This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors. Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1. Research procedures include: * In depth interview (lymphoma and mental health clinicians) * Screening for eligibility * 6 weekly intervention sessions (lymphoma survivors) * Baseline Assessments and Questionnaires (lymphoma survivors) 74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2. The American Society of Hematology is providing funding for the trial.

Arms & interventions

OtherInterview with Clinicians
One time, qualitative interview of clinicians for feedback on UPLYFT intervention
OtherField Test of UPLYFT with Lymphoma Survivors
6 session of UPLYFT intervention with Lymphoma Survivors for feedback
BehavioralPilot of UPLYFT with Lymphoma Survivors
6 session of UPLYFT intervention with Lymphoma Survivors

Outcome measures

Primary

Feasibility: Enrollment Rate
Proportion of eligible patients approached that enroll in the study.
Time frame: Up to 6 months
Feasibility: Program Session Completion Rate
Proportion of study participants randomized to the intervention arm (UPLYFT) who complete all intervention sessions.
Time frame: Up to 6 months
Feasibility: Data Collection Completion Rate
Proportion of enrolled participants who complete assigned patient-reported questionnaires during the study.
Time frame: Up to 6 months

Secondary

Acceptability: Satisfaction Rate
Time frame: Up to 6 months
Acceptability: Disenrollment Rate
Time frame: Up to 6 months
Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change
Time frame: Up to 6 months
Preliminary efficacy: Quality of Life Change
Time frame: Up to 6 months
Preliminary efficacy: Anxiety Change
Time frame: Up to 6 months
Preliminary efficacy: Depression Change
Time frame: Up to 6 months
Preliminary efficacy: Psychological inflexibility Change
Time frame: Up to 6 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No

Inclusion Criteria: Lymphoma Survivors Phase 1 and 2: * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma) * Age ≥ 18 years * Interval of 3 months to 24 months from completion of first-line treatment * In complete remission after first line of treatment * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS). * Access to computer (for videoconferencing) Lymphoma clinicians and mental health clinicians Phase 1: * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training. * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians Exclusion Criteria: Lymphoma Survivors Phase 1: * Age \< 18 years * Concurrent other malignancy * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen). Lymphoma Survivors Phase 2: * Age \< 18 years * Concurrent other malignancy * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen). * Our study will exclude members of the following special populations: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners

Study locations (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Recruiting

Oreofe O Odejide, MD, MPH · Contact

617-632-6864 Oreofe_Odejide@dfci.harvard.edu

Oreofe O Odejide, MD, MPH · Principal Investigator